PhRMA Delegation Meets China Pharmaceutical Organizations
This article was originally published in PharmAsia News
Representatives from the Pharmaceutical Research and Manufacturers of America recently attended an international summit in Beijing on new drug R&D policies and practices hosted by the Healthcare Policy Research Center of Chinese Pharmaceutical Association. The center expressed the wish of strengthening both countries' cooperation in drug production to the American delegation, which included top-level executives from key multinational companies such as Bristol-Myers Squibb, Lilly, Genzyme, GlaxoSmithKline, MSD Pharma (Merck's India arm), Novartis, Pfizer, Schering-Plough and Wyeth. The U.S. group held exchanges with officials from China's State FDA and the Ministry of Health on supervisory issues about developing new drugs globally and conducting multicenter clinical trials. Members from China Health & Medical Development Foundation, Chinese Pharmaceutical Association and China Pharmaceutical Industry Association also joined in discussions to boost collaboration. (Click here for more - Chinese Language)
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.